+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Ischemic Agents Market by Drug Class, Route Of Administration, End User, Distribution Channel, Application - Global Forecast to 2030- Product Image
Anti-Ischemic Agents Market by Drug Class, Route Of Administration, End User, Distribution Channel, Application - Global Forecast to 2030- Product Image
Sale

Anti-Ischemic Agents Market by Drug Class, Route Of Administration, End User, Distribution Channel, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887511
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Ischemic Agents Market grew from USD 378.99 million in 2024 to USD 402.92 million in 2025. It is expected to continue growing at a CAGR of 6.20%, reaching USD 543.77 million by 2030.

Setting the Stage for Anti-Ischemic Agents Market Dynamics

The anti-ischemic agents sector stands at a critical intersection of clinical need and scientific innovation. Rising prevalence of ischemic cardiovascular disorders worldwide underscores an urgent demand for therapies that not only manage symptoms but also improve long-term patient outcomes. Against this backdrop, industry stakeholders face mounting pressures-from patent expirations to evolving regulatory frameworks-that reshape product pipelines and competitive dynamics. This executive summary offers a structured overview of current market drivers, key trends, and strategic imperatives that inform investment and development decisions. It sets out the foundational context for understanding how therapeutic modalities, stakeholder behaviors, and policy environments converge to create both challenges and opportunities. By synthesizing complex data into actionable insights, this introduction paves the way for a deeper exploration of transformative shifts, tariff impacts, segmentation nuances, regional distinctions, and the strategies of leading companies.

Unveiling Transformative Shifts in the Anti-Ischemic Agent Arena

The landscape of anti-ischemic therapy is undergoing transformative shifts driven by scientific breakthroughs and changing care models. Innovation in drug delivery technologies has accelerated the adoption of sublingual sprays and transdermal systems, offering patients faster relief and improved adherence compared with traditional oral formulations. Simultaneously, the patent expirations of blockbuster ACE inhibitors and beta blockers have paved the way for rapid generic uptake, compressing margins for established brands while expanding access in emerging markets. Personalized medicine initiatives are gaining traction as biomarkers and genetic profiling inform patient-specific treatment regimens, challenging conventional one-size-fits-all approaches. Digital health platforms further augment these shifts, enabling remote monitoring of hemodynamic parameters and adherence, thereby blurring the lines between pharmacotherapy and digital therapeutics. Partnerships between biotech firms and technology companies illustrate the convergence of disciplines, fostering combination therapies that integrate pharmacologic agents with wearable sensors. Taken together, these developments signal a departure from incremental innovation toward holistic, patient-centric care pathways that redefine how ischemic events are prevented and managed.

Assessing the Cumulative Impact of US Tariffs in 2025 on Anti-Ischemic Therapeutics

The introduction of United States tariffs on active pharmaceutical ingredients and excipients in 2025 has reverberated across the supply chain, reshaping cost structures and sourcing strategies. With a substantial share of raw materials historically imported, manufacturers have confronted sudden escalations in input costs that erode profitability and prompt renegotiation of supplier agreements. Companies reliant on Chinese and Indian API producers have accelerated efforts to diversify their supplier base, exploring onshore and nearshore alternatives to mitigate future duties. Meanwhile, the pressure to maintain competitive pricing has led some organizations to revisit formulation strategies, seeking to optimize production yields and streamline downstream processing. Smaller generic producers, operating on thinner margins, have been particularly vulnerable to these shifts, with some reconsidering market exits or consolidation to achieve economies of scale. In response, leading players have leveraged integrated supply chain models, investing in backward integration and entering strategic partnerships with domestic chemical manufacturers. These moves not only cushion against tariff volatility but also bolster supply resilience, ensuring continuity in anti-ischemic therapy availability amid a dynamic trade environment.

Key Segmentation Insights Revealing Market Nuances

Examining the market through multiple lenses reveals deep insights into competitive positioning and growth prospects. When viewed by drug class, the landscape encompasses ACE inhibitors, beta blockers, calcium channel blockers, and nitrates, each with distinct therapeutic profiles and lifecycle trajectories. Analyzing the subcategories of beta blockers illuminates differential uptake between non-selective and cardioselective formulations, while disaggregating calcium channel blockers highlights the divergent pathways of dihydropyridines versus non-dihydropyridines. Oral, sublingual, and transdermal forms of nitrates demonstrate varying patient adherence patterns and onset times. The route of administration segmentation, spanning intravenous bolus and continuous infusion to extended-release oral and spray-based sublingual systems, further refines understanding of acute versus chronic management. Insight into end users-from outpatient ambulatory surgical centers to hospital cardiology and emergency departments-uncovers where therapeutic demand is most acute and where home care penetration offers expansion opportunities. Distribution channels ranging from private and public hospital pharmacies to e-pharmacies and mail-order services illustrate shifting procurement behaviors, while chain and independent retail outlets underscore the importance of reach and brand visibility. Finally, the split between acute management in hospital settings and pre-hospital emergencies versus long-term and short-term prophylaxis informs portfolio prioritization and patient support programs.

Regional Dynamics Shaping the Anti-Ischemic Agents Market

Regional dynamics exert a profound influence on market development, shaping regulatory frameworks, reimbursement policies, and competitive intensity. In the Americas, high healthcare expenditure and a broad network of tertiary hospitals drive demand for advanced therapeutic options, compelling manufacturers to balance premium pricing with managed care negotiations. Latin American markets continue to expand generics uptake as cost pressures mount, creating dual pathways for branded and off-patent products. Europe, Middle East & Africa present a mosaic of market conditions: stringent pricing controls in Western Europe contrast with emerging consumption growth in Gulf Cooperation Council countries, while Africa’s uneven healthcare infrastructure poses distribution challenges alongside untapped potential. Asia-Pacific stands out for its rapid urbanization and rising incidence of ischemic conditions, fueling demand for both innovative agents and affordable generics. Local production capabilities in China, India, and South Korea foster competitive domestic players, while regulatory harmonization efforts under the ASEAN framework gradually streamline regional market entry. Each geography demands tailored strategies that reflect patient access considerations, payer landscapes, and the pace of healthcare modernization.

Competitive Intelligence on Leading Anti-Ischemic Players

The competitive landscape features a mix of established pharmaceutical giants, nimble generic manufacturers, and innovative biotechs advancing novel mechanisms. Legacy companies maintain strong brand loyalty through long-standing relationships with cardiology specialists, leveraging extensive clinical trial data and global distribution networks. Generic entrants, benefitting from streamlined regulatory pathways, aggressively target high-volume segments, driving down prices and expanding market penetration in cost-sensitive regions. Biopharmaceutical firms, meanwhile, concentrate on next-generation formulations and combination therapies, seeking differentiation through improved pharmacokinetics and patient compliance features. Strategic collaborations between incumbent players and technology vendors are emerging, focusing on digital adherence tools and remote patient monitoring services. Mergers and acquisitions remain a key tactic for capacity expansion, particularly in API manufacturing and formulation development. In parallel, contract development and manufacturing organizations gain prominence as outsourced partners, enabling agile scale-up and cost optimization. Observing these competitive moves provides clarity on where the market’s value is migrating and how organizations can position themselves to capture growth driven by innovation and efficiency.

Strategic Recommendations to Advance Market Positioning

To thrive in a market defined by rapid change, industry leaders must adopt a multifaceted approach. Diversifying the supplier ecosystem through dual sourcing and strategic partnerships will safeguard against trade disruptions and tariff fluctuations. Enhancing portfolios with both acute management and prophylactic offerings ensures resilience amid shifting treatment paradigms, while investing in digital therapeutics and remote monitoring platforms can deepen patient engagement and adherence. Collaborating with payers to establish value-based contracts and real-world evidence studies will support premium pricing and favorable reimbursement. Pursuing targeted acquisitions or joint ventures in emerging markets can accelerate geographic expansion and local regulatory navigation. Additionally, embedding sustainability and ethical sourcing in supply chains will resonate with stakeholders increasingly sensitive to corporate responsibility. By aligning research and development pipelines with epidemiological trends and regulatory forecasts, companies can anticipate unmet needs and streamline time to market. Together, these measures equip organizations to outmaneuver competitors and deliver superior clinical and commercial performance.

Robust Research Methodology Underpinning the Analysis

This report integrates rigorous primary and secondary research to deliver a robust analysis of the anti-ischemic agents market. Secondary efforts encompassed review of financial reports, regulatory filings, industry publications, and patent databases to establish foundational market intelligence. Complementing this, over fifty in-depth interviews were conducted with C-suite executives, clinical experts, commercial leaders, and procurement specialists to capture qualitative insights into market drivers and barriers. Quantitative data was triangulated from publicly available sources, proprietary databases, and customized surveys, enabling validation across multiple independent datasets. The segmentation framework was constructed using market share, volume, and revenue metrics, ensuring each category’s relevance to strategic decision-making. Rigorous data cleansing and statistical modeling underpinned trend analyses, while scenario planning assessed the potential impacts of policy changes and technological disruptions. Throughout, an iterative review process with stakeholders fortified the credibility of conclusions and recommendations, providing a transparent and replicable methodology for future updates.

Concluding Reflections on Anti-Ischemic Agents Market Evolution

The anti-ischemic agents market is poised at a crossroads where innovation, regulation, and shifting patient needs converge to create both formidable challenges and compelling opportunities. The ongoing transformation of drug delivery formats, the reverberations of global trade policies, and the evolving tapestry of healthcare infrastructures across regions necessitate strategic agility. Companies that harness segmentation insights, embrace digital integration, and cultivate resilient supply chains will be best positioned to capture emerging value. As the competitive environment intensifies, a clear understanding of regional nuances and stakeholder priorities becomes indispensable. This analysis underscores the imperative for informed decision-making anchored in rigorous data and forward-looking scenarios. Moving confidently from insight to action will define leaders in the next chapter of anti-ischemic therapy development and commercialization.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Ace Inhibitors
    • Beta Blockers
      • Non Selective
      • Selective
    • Calcium Channel Blockers
      • Dihydropyridines
      • Non Dihydropyridines
    • Nitrates
      • Oral
      • Sublingual
      • Transdermal
  • Route Of Administration
    • Intravenous
      • Bolus
      • Continuous Infusion
    • Oral
      • Extended Release
      • Immediate Release
    • Sublingual
      • Spray
      • Tablet
    • Transdermal
      • Ointment
      • Patch
  • End User
    • Clinics
      • Ambulatory Surgical Centers
      • Outpatient Centers
    • Home Care
    • Hospitals
      • Cardiology Departments
      • Emergency Departments
  • Distribution Channel
    • Hospital Pharmacies
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacies
      • E Pharmacy
      • Mail Order
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • Application
    • Acute Management
      • Hospital Settings
      • Pre Hospital Emergencies
    • Prophylaxis
      • Long Term Prophylaxis
      • Short Term Prophylaxis
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Ischemic Agents Market, by Drug Class
8.1. Introduction
8.2. Ace Inhibitors
8.3. Beta Blockers
8.3.1. Non Selective
8.3.2. Selective
8.4. Calcium Channel Blockers
8.4.1. Dihydropyridines
8.4.2. Non Dihydropyridines
8.5. Nitrates
8.5.1. Oral
8.5.2. Sublingual
8.5.3. Transdermal
9. Anti-Ischemic Agents Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Bolus
9.2.2. Continuous Infusion
9.3. Oral
9.3.1. Extended Release
9.3.2. Immediate Release
9.4. Sublingual
9.4.1. Spray
9.4.2. Tablet
9.5. Transdermal
9.5.1. Ointment
9.5.2. Patch
10. Anti-Ischemic Agents Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Ambulatory Surgical Centers
10.2.2. Outpatient Centers
10.3. Home Care
10.4. Hospitals
10.4.1. Cardiology Departments
10.4.2. Emergency Departments
11. Anti-Ischemic Agents Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.2.1. Private Hospitals
11.2.2. Public Hospitals
11.3. Online Pharmacies
11.3.1. E Pharmacy
11.3.2. Mail Order
11.4. Retail Pharmacies
11.4.1. Chain Pharmacies
11.4.2. Independent Pharmacies
12. Anti-Ischemic Agents Market, by Application
12.1. Introduction
12.2. Acute Management
12.2.1. Hospital Settings
12.2.2. Pre Hospital Emergencies
12.3. Prophylaxis
12.3.1. Long Term Prophylaxis
12.3.2. Short Term Prophylaxis
13. Americas Anti-Ischemic Agents Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-Ischemic Agents Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-Ischemic Agents Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Novartis AG
16.3.4. Bayer AG
16.3.5. AstraZeneca PLC
16.3.6. GlaxoSmithKline plc
16.3.7. Sanofi S.A.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Merck & Co., Inc.
16.3.10. Gilead Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-ISCHEMIC AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NON SELECTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SELECTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DIHYDROPYRIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NON DIHYDROPYRIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY E PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PRE HOSPITAL EMERGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 112. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 113. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 114. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 116. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 118. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 119. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 121. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 126. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 128. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 133. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 144. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 147. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 225. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 227. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 229. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 236. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 239. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 240. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 241. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 243. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 244. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 248. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 253. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 258. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 259. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 262. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 281. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 282. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 284. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 285. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 286. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 288. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 289. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 290. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 291. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 296. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 297. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 300. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 301. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 303. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 304. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 305. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 307. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 308. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 309. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 310. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 312. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 315. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 316. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 317. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ACUTE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 319. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY NITRATES, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 335. U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Ischemic Agents market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 402.92 Million
Forecasted Market Value ( USD ) by 2030 $ 543.77 Million
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Ischemic Agents - Global Strategic Business Report - Product Image

Anti-Ischemic Agents - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Ischemic Heart Disease (IHD) Drugs Market Report 2025 - Product Image

Ischemic Heart Disease (IHD) Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ischemic Heart Disease (IHD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Ischemic Heart Disease (IHD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Angina Pectoris Drugs Market Report 2025 - Product Image

Angina Pectoris Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ischemic Heart Disease (IHD) Drugs - Global Strategic Business Report - Product Image

Ischemic Heart Disease (IHD) Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Ischemic Attack Drug Market

The Ischemic Attack Drug market is a subset of the Cardiovascular Drugs market, which focuses on drugs used to treat ischemic attacks, also known as ischemic strokes. Ischemic attacks are caused by a blockage in the blood vessels that supply blood to the brain, and can lead to permanent brain damage or death. Ischemic attack drugs are used to reduce the risk of stroke and improve the patient's quality of life. These drugs can be administered orally, intravenously, or through a catheter. Commonly used ischemic attack drugs include aspirin, clopidogrel, and ticagrelor. Some of the major companies in the Ischemic Attack Drug market include Pfizer, Merck, Sanofi, Bristol-Myers Squibb, and GlaxoSmithKline. These companies produce a variety of ischemic attack drugs, including aspirin, clopidogrel, and ticagrelor. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.